Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Breast Cancer Metastasis to the Central Nervous System
2005
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Lapatinib
2007
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer
2006
Primary breast cancer phenotypes associated with propensity for central nervous system metastases
2006
First-line chemotherapy for NSCLC: an overview of relevant trials
2002
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
2009 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Genes that mediate breast cancer metastasis to the brain
2009 StandoutNature
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Contribution of platelets to tumour metastasis
2011 Standout
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR
2006
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594
2001
Neurocognitive Function of Patients with Brain Metastasis Who Received Either Whole Brain Radiotherapy Plus Stereotactic Radiosurgery or Radiosurgery Alone
2007
Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays
1997
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens
2001
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
1995
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
Isolation of rare circulating tumour cells in cancer patients by microchip technology
2007 StandoutNature
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
2001
Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer
2000
Lung cancer: current therapies and new targeted treatments
2016 Standout
Cancer genes and the pathways they control
2004 Standout
Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer
2005
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Cellular processing of platinum anticancer drugs
2005 Standout
Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression
2001 StandoutNobel
Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer
2007
Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results
2001
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine
2001
Malignant Gliomas in Adults
2008 Standout
The health-related quality of life and survival of small-cell lung cancer patients: Results of a companion study to CALGB 9033
2002
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial
2004
Brachytherapy for Non-small Cell Lung Cancer and Selected Neoplasms of the Chest
1997
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
The Benefits of Frequent Positive Affect: Does Happiness Lead to Success?
2005 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
2006
Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923
2002
Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells
1996
Role of gemcitabine in cancer therapy
2005
Regulation of Vascularization by Hypoxia‐Inducible Factor 1
2009 StandoutNobel
Microtubules as a target for anticancer drugs
2004 Standout
A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
2000
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Photodynamic Therapy
2000
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC
2004
HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors
2002 StandoutNobel
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Factors affecting the prognosis of breast cancer patients with brain metastases
2008
Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
2002
Monitoring tumour cells in the peripheral blood of small cell lung cancer patients
2002
Platinum drugs in the treatment of non-small-cell lung cancer
2002
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Advances in Malignant Mesothelioma
2005 Standout
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration
2008 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Trastuzumab in the management of early and advanced stage breast cancer.
2007
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases
2016 Standout
Applications of magnetic nanoparticles in biomedicine
2003 Standout
Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
2006
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
2001
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
DNA Double-Strand Breaks
2002 StandoutNobel
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Second-line chemotherapy for non-small cell lung cancer
2002
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of P.A. Burt being referenced
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
2004
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome
2000
Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
1991
The intrinsic radiosensitivity of cervical carcinoma: correlations with clinical data
1995
Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma
2001
High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients
1994
Massive haemoptysis death and other morbidity associated with high dose rate intraluminal radiotherapy for carcinoma of the bronchus
1996
Intraluminal brachytherapy using the high dose rate microSelectron in the palliation of carcinoma of the oesophagus
1995
Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation
1994
Intensive combined-modality therapy in small cell lung cancer
1995
Dose intensity in small cell lung cancer.
1998
Use of Hematopoietic Progenitors in Whole Blood to Support Dose-Dense Chemotherapy: A Randomized Phase II Trial in Small-Cell Lung Cancer Patients
2001
24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC)
1997
Neurological and cognitive impairment in long-term survivors of small cell lung cancer
1994